Resveratrol improves survival and prolongs life following hemorrhagic shock

Molecular Medicine

Volumn 21, Issue , 2015, Pages 305-312

  Ayub, Ahmar ^a   Poulose, Ninu ^a   Raju, Raghavan ^a,b  

^a AUGUSTA UNIVERSITY   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOCHONDRIAL TRANSCRIPTION FACTOR A; N [2 [3 (1 PIPERAZINYLMETHYL)IMIDAZO[2,1 B]THIAZOL 6 YL]PHENYL] 2 QUINOXALINECARBOXAMIDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PLACEBO; RESVERATROL; ANTIOXIDANT; STILBENE DERIVATIVE;

ADD ON THERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; FLUID RESUSCITATION; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE DP-DT; HEART LEFT VENTRICLE FUNCTION; HEART MITOCHONDRION; HEART MUSCLE CONTRACTILITY; HEMORRHAGIC SHOCK; LIFE EXTENSION; LIFE SUSTAINING TREATMENT; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; RAT MODEL; SURVIVAL; SURVIVAL TIME; TISSUE DISTRIBUTION; ANIMAL; CARDIAC MUSCLE; DISEASE MODEL; KAPLAN MEIER METHOD; METABOLISM; MORTALITY; SEVERITY OF ILLNESS INDEX; SHOCK, HEMORRHAGIC; TIME FACTOR;

ANIMALS; ANTIOXIDANTS; DISEASE MODELS, ANIMAL; KAPLAN-MEIER ESTIMATE; MALE; MORTALITY; MYOCARDIUM; RATS; SEVERITY OF ILLNESS INDEX; SHOCK, HEMORRHAGIC; STILBENES; TIME FACTORS;

EID: 84937544271     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2015.00013     Document Type: Article

References (49)

1. Minino AM, Anderson RN, Fingerhut LA, Boudreault MA, Warner M. (2006) Deaths: injuries, 2002. National vital statistics reports: from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System 54:1-124.
2. Spinella PC, Holcomb JB. (2009) Resuscitation and transfusion principles for traumatic hemorrhagic shock. Blood Rev. 23:231-40.
3. Kauvar DS, Lefering R, Wade CE. (2006) Impact of hemorrhage on trauma outcome: an overview of epidemiology, clinical presentations, and therapeutic considerations. J. Trauma. 60:S3-11.
4. Curry N, et al. (2011) The acute management of trauma hemorrhage: a systematic review of randomized controlled trials. Crit. Care. 15:R92.
5. Magnotti LJ, et al. (2011) Improved survival after hemostatic resuscitation: does the emperor have no clothes? J. Trauma. 70:97-102.
6. McSwain NE, et al. (2011) State of the art of fluid resuscitation 2010: prehospital and immediate transition to the hospital. J. Trauma. 70:S2-10.
7. Poulose N, Raju R. (2014) Aging and injury: alterations in cellular energetics and organ function. Aging Dis. 5:101-8.
8. Raju R, Bland KI, Chaudry IH. (2008) Estrogen: a novel therapeutic adjunct for the treatment of trauma-hemorrhage-induced immunological alterations. Mol. Med. 14:213-21.
9. Thacker SA, Robinson P, Abel A, Tweardy DJ. (2013) Modulation of the unfolded protein response during hepatocyte and cardiomyocyte apoptosis in trauma/hemorrhagic shock. Sci. Rep. 3:1187.
10. Hierholzer C, et al. (1998) Interleukin-6 production in hemorrhagic shock is accompanied by neutrophil recruitment and lung injury. Am. J. Physiol. 275:L611-621.
11. Villarroel JP, et al. (2013) Hemorrhagic shock and resuscitation are associated with peripheral blood mononuclear cell mitochondrial dysfunction and immunosuppression. J. Trauma Acute Care Surg. 75:24-31.
12. Fishman JE, et al. (2013) Oxidative modification of the intestinal mucus layer is a critical but unrecognized component of trauma hemorrhagic shock-induced gut barrier failure. Am. J. Physiol. Gastrointest. Liver Physiol. 304: G57-63.
13. Hsieh CH, et al. (2009) Trauma-hemorrhage and hypoxia differentially influence kupffer cell phagocytic capacity: role of hypoxia-induciblefactor-1alpha and phosphoinositide 3-kinase/Akt activation. Ann. Surg. 250:995-1001.
14. Kan WH, et al. (2008) Flutamide protects against trauma-hemorrhage-induced liver injury via attenuation of the inflammatory response, oxidative stress, and apoptosis. J. Appl. Physiol. (1985) 105:595-602.
15. Sawant DA, Tharakan B, Hunter FA, Childs EW. (2014) The role of intrinsic apoptotic signaling in hemorrhagic shock-induced microvascular endothelial cell barrier dysfunction. J. Cardiovasc. Transl. Res. 7:711-18.
16. Escobales N, et al. (2014) Mitochondria-targeted ROS scavenger improves post-ischemic recovery of cardiac function and attenuates mitochondrial abnormalities in aged rats. J. Mol. Cell. Cardiol. 77:136-46.
17. Schumacker PT, et al. (2014) Mitochondria in lung biology and pathology: more than just a powerhouse. Am. J. Physiol. Lung Cell. Mol. Physiol. 306:L962-74.
18. Wallace DC. (2011) Bioenergetic origins of complexity and disease. Cold Spring Harb. Symp. Quant. Biol. 76:1-16.
19. Chen YR, Zweier JL. (2014) Cardiac mitochondria and reactive oxygen species generation. Circ. Res. 114:524-37.
20. Chen T, et al. (2014) Activation of SIRT3 by resveratrol ameliorates cardiac fibrosis and improves cardiac function via TGF-β/Smad3 pathway. Am. J. Physiol. Heart Circ. Physiol. 308:H424-34.
21. Catalgol B, Batirel S, Taga Y, Ozer NK. (2012) Resveratrol: French paradox revisited. Front. Pharmacol. 3:141.
22. Wang R, et al. (2014) Resveratrol protects neurons and the myocardium by reducing oxidative stress and ameliorating mitochondria damage in a cerebral ischemia rat model. Cell. Physiol. Biochem. 34:854-64.
23. Jian B, Yang S, Chaudry IH, Raju R. (2012) Resveratrol improves cardiac contractility following trauma-hemorrhage by modulating Sirt1. Mol. Med. 18:209-14.
24. Wang H, et al. (2014) Resveratrol ameliorates mitochondrial dysfunction but increases the risk of hypoglycemia following hemorrhagic shock. J. Trauma Acute Care Surg. 77:926-933.
25. Wu CT, Yu HP, Chung CY, Lau YT, Liao SK. (2008) Attenuation of lung inflammation and pro-inflammatory cytokine production by resveratrol following trauma-hemorrhage. Chin. J. Physiol. 51:363-8.
26. Baur JA, et al. (2006) Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 444:337-42.
27. Price NL, et al. (2012) SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 15:675-90.
28. Ferretta A, et al. (2014) Effect of resveratrol on mitochondrial function: implications in parkinassociated familiar Parkinson’s disease. Biochim. Biophys. Acta. 1842:902-15.
29. Valero T. (2014) Mitochondrial biogenesis: pharmacological approaches. Curr. Pharm. Des. 20:5507-9.
30. Tsai YF, Liu FC, Lau YT, Yu HP. (2012) Role of Aktdependent pathway in resveratrol-mediated cardioprotection after trauma-hemorrhage. J. Surg. Res. 176:171-7.
31. Sinclair DA, Guarente L. (2014) Small-molecule allosteric activators of sirtuins. Annu. Rev. Pharmacol. Toxicol. 54:363-80.
32. Park SJ, et al. (2012) Resveratrol ameliorates aging-related metabolic phenotypes by inhibiting cAMP phosphodiesterases. Cell. 148:421-33.
33. Sajish M, Schimmel P. (2014) A human tRNA synthetase is a potent PARP1-activating effector target for resveratrol. Nature. 519:370-3.
34. Baur JA, Ungvari Z, Minor RK, Le Couteur DG, de Cabo R. (2012) Are sirtuins viable targets for improving healthspan and lifespan? Nat. Rev. Drug Discov. 11:443-61.
35. Allard JS, Perez E, Zou S, de Cabo R. (2009) Dietary activators of Sirt1. Mol. Cell. Endocrinol. 299:58-63.
36. Ba ZF, Chaudry IH. (2008) Role of estrogen receptor subtypes in estrogen-induced organ-specific vasorelaxation after trauma-hemorrhage. Am. J. Physiol. Heart. Circ. Physiol. 295:H2061-7.
37. Yu HP, Chaudry IH. (2009) The role of estrogen and receptor agonists in maintaining organ function after trauma-hemorrhage. Shock. 31:227-37.
38. Gano LB, et al. (2014) The SIRT1 activator SRT1720 reverses vascular endothelial dysfunction, excessive superoxide production, and inflammation with aging in mice. Am. J. Physiol. Heart. Circ. Physiol. 307:H1754-63.
39. Mitchell SJ, et al. (2014) The SIRT1 activator SRT1720 extends lifespan and improves health of mice fed a standard diet. Cell Rep. 6:836-43.
40. Yang SH, et al. (2014) Cardioprotection by estrogen related receptor (ERR)-beta and-gamma agonist DY131 after trauma-hemorrhage (T-H) is via DY131-derived restoration of cardiac sirtuins (SIRT) [Abstract]. Shock. 41 Suppl 2:63-4.
41. Kentner R, et al. (2002) Early antioxidant therapy with Tempol during hemorrhagic shock increases survival in rats. J. Trauma. 53:968-77.
42. Gazmuri RJ, Radhakrishnan J. (2012) Protecting mitochondrial bioenergetic function during resuscitation from cardiac arrest. Crit. Care Clin. 28:245-270.
43. Szabo C, Modis K. (2010) Pathophysiological roles of peroxynitrite in circulatory shock. Shock. 34 Suppl 1:4-14.
44. Powell RD, et al. (2015) MitoQ modulates oxidative stress and decreases inflammation following hemorrhage. J. Trauma Acute Care Surg. 78:573-9.
45. Shen Q, et al. (2014) Ubiquinol decreases hemorrhagic shock/resuscitation-induced microvascular inflammation in rat mesenteric microcirculation. Physiol. Rep. 2.pii:e12199.
46. Li H, Horke S, Forstermann U. (2013) Oxidative stress in vascular disease and its pharmacological prevention. Trends Pharmacol. Sci. 34:313-9.
47. Juan SH, Cheng TH, Lin HC, Chu YL, Lee WS. (2005) Mechanism of concentration-dependent induction of heme oxygenase-1 by resveratrol in human aortic smooth muscle cells. Biochem. Pharmacol. 69:41-8.
48. Carrizzo A, et al. (2013) Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases. Food Chem. Toxicol. 61:215-26.
49. Pangeni R, Sahni JK, Ali J, Sharma S, Baboota S. (2014) Resveratrol: review on therapeutic potential and recent advances in drug delivery. Expert Opin. Drug Deliv. 11:1285-98.